Myosin Inhibitor Therapy in Athletic Heart with HCM-Like Features and Possible Obstruction
The critical first step is to definitively distinguish true hypertrophic cardiomyopathy from physiologic athletic remodeling, because myosin inhibitors (mavacamten, aficamten) are only indicated for confirmed obstructive HCM and would be inappropriate—and potentially harmful—in pure athletic heart. 1
Diagnostic Clarification Required
Your 20+ year athletic heart with "HCM-like thickening" and "possible obstruction" represents a diagnostic gray zone that must be resolved before considering myosin inhibitors:
Features Favoring True HCM Over Athletic Heart:
- Left ventricular wall thickness >15 mm (athletic heart rarely exceeds 13-14 mm)
- Asymmetric septal hypertrophy (athletic heart shows concentric patterns)
- Resting or provoked LVOT gradient ≥30 mmHg
- Left atrial enlargement disproportionate to LV size
- Diastolic dysfunction beyond what deconditioning would explain
- Positive genetic testing for sarcomeric mutations
- Late gadolinium enhancement on cardiac MRI (suggests fibrosis, not seen in athletic heart)
- Failure of hypertrophy to regress after 3-6 months of detraining
Critical Diagnostic Steps:
- Cardiac MRI with late gadolinium enhancement to assess for fibrosis 2
- Exercise stress echocardiography to provoke latent LVOT obstruction 3
- Genetic testing for sarcomeric mutations
- Consider 3-6 month detraining period if diagnosis remains uncertain (athletic heart will regress; HCM will not)
If Confirmed Obstructive HCM: Myosin Inhibitor Eligibility
Myosin inhibitors are Class 1 recommended for adults with obstructive HCM who remain symptomatic despite beta-blockers or non-dihydropyridine calcium channel blockers. 1
Specific Criteria for Mavacamten or Aficamten:
Inclusion criteria:
- Confirmed HCM diagnosis (not athletic heart)
- LVOT gradient ≥30 mmHg (resting or provoked with Valsalva) 4
- LVEF ≥55% at baseline 2
- Persistent symptoms (dyspnea, chest pain, near-syncope) despite first-line therapy
- Adult patient (not approved for pediatrics)
Absolute contraindications:
- LVEF <55% 2, 4
- Pregnancy or potential pregnancy (teratogenic) 1, 5, 4
- Pure athletic heart without true HCM
Monitoring Requirements if Initiated
Mandatory echocardiographic surveillance is required due to risk of excessive LVEF reduction (5.7-10% of patients). 2, 1
Monitoring Protocol:
- Monthly echocardiograms for first 3 months
- Every 3 months thereafter 2
- Temporarily discontinue if LVEF drops <50% 2, 4
- Permanently discontinue if LVEF <30% 2
Clinical Efficacy Data
Mavacamten reduces LVOT gradients by 35-49 mmHg and improves symptoms, but only 37% of patients meet primary efficacy endpoints despite dose titration. 2 The remaining patients show partial benefit with gradient reduction and biomarker improvement 2.
Aficamten demonstrates similar gradient reductions (-35 mmHg resting, -48 mmHg Valsalva) with comparable LVEF safety profile. 6
Alternative Therapies if Myosin Inhibitors Inappropriate
If this proves to be athletic heart or if LVEF is borderline:
First-line options:
- Non-vasodilating beta-blockers (metoprolol, atenolol) titrated to physiologic effect 1, 2
- Verapamil or diltiazem if beta-blockers ineffective (caution: avoid if very high gradients >100 mmHg or severe symptoms at rest) 1, 7
Second-line:
- Disopyramide (with AV nodal blocker to prevent rapid AF conduction) 1
Invasive options:
Critical Pitfalls to Avoid
- Do not use myosin inhibitors without confirmed HCM diagnosis—athletic heart requires no treatment beyond possible activity modification
- Do not initiate if LVEF <55%—risk of symptomatic heart failure 2
- Avoid vasodilators (ACE inhibitors, ARBs, dihydropyridine CCBs) if obstruction confirmed—these worsen LVOT gradients 1, 7
- Do not skip mandatory echocardiographic monitoring—LVEF reduction can occur unpredictably 2, 1
Bottom line: Resolve the athletic heart vs. true HCM question definitively before considering myosin inhibitors. If confirmed obstructive HCM with LVEF ≥55% and persistent symptoms despite conventional therapy, myosin inhibitors are appropriate and guideline-recommended, but require rigorous monitoring. 1